135 related articles for article (PubMed ID: 28119362)
1. LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab.
Bonanno L; De Paoli A; Zulato E; Esposito G; Calabrese F; Favaretto A; Santo A; Conte AD; Chilosi M; Oniga F; Sozzi G; Moro M; Ciccarese F; Nardo G; Bertorelle R; Candiotto C; De Salvo GL; Amadori A; Conte P; Indraccolo S
Clin Cancer Res; 2017 Jul; 23(13):3316-3324. PubMed ID: 28119362
[No Abstract] [Full Text] [Related]
2. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Franzini A; Baty F; Macovei II; Dürr O; Droege C; Betticher D; Grigoriu BD; Klingbiel D; Zappa F; Brutsche MH
Clin Cancer Res; 2015 Dec; 21(23):5253-63. PubMed ID: 25922429
[TBL] [Abstract][Full Text] [Related]
3. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Nishijima-Futami Y; Minami S; Futami S; Koba T; Higashiguchi M; Tamiya M; Suzuki H; Hirashima T; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1215-1220. PubMed ID: 28455584
[TBL] [Abstract][Full Text] [Related]
6. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
7. Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
Wills B; Cardona AF; Rojas L; Ruiz-Patiño A; Arrieta O; Reguart N; Carranza H; Vargas C; Otero J; Corrales L; Martín C; Cuello M; Pino LE; Rolfo C; Rosell R; Zatarain-Barrón ZL;
Anticancer Res; 2017 Nov; 37(11):6429-6436. PubMed ID: 29061829
[TBL] [Abstract][Full Text] [Related]
8. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
Rodríguez Garzotto A; Díaz-García CV; Agudo-López A; Prieto García E; Ponce S; López-Martín JA; Paz-Ares L; Iglesias L; Agulló-Ortuño MT
Med Oncol; 2016 Oct; 33(10):105. PubMed ID: 27568331
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).
Bennouna J; Falchero L; Schott R; Bonnetain F; Coudert M; Ben Hadj Yahia B; Chouaid C
Oncology; 2018; 94(1):55-64. PubMed ID: 29065416
[TBL] [Abstract][Full Text] [Related]
10. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
Ishikura N; Yanagisawa M; Noguchi-Sasaki M; Iwai T; Yorozu K; Kurasawa M; Sugimoto M; Yamamoto K
Anticancer Res; 2017 Feb; 37(2):623-629. PubMed ID: 28179309
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
12. MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
Hiura K; Shiraishi A; Suzuki C; Takamura K; Yamamoto M; Komori H; Watanabe Y; Iwaki-Egawa S
Cancer Biomark; 2015; 15(4):433-40. PubMed ID: 25835177
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study.
Leon L; Kosty M; Jahanzeb M; Spigel D; Wozniak AJ; Brahmer J; Fish S; Flick ED; Hazard SJ; Lynch TJ
Pharmacoepidemiol Drug Saf; 2016 May; 25(5):569-77. PubMed ID: 26748833
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
[TBL] [Abstract][Full Text] [Related]
15. Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.
Yang R; Li SW; Chen Z; Zhou X; Ni W; Fu DA; Lu J; Kaye FJ; Wu L
J Natl Cancer Inst; 2019 Jul; 111(7):664-674. PubMed ID: 30423141
[TBL] [Abstract][Full Text] [Related]
16. [Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study].
Chouaid C; Falchero L; Schott R; Bonnetain F; Taguieva-Pioger N; Bennouna J
Rev Mal Respir; 2017 Jan; 34(1):36-43. PubMed ID: 27266900
[TBL] [Abstract][Full Text] [Related]
17. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
18. Metformin: a modulator of bevacizumab activity in cancer? A case report.
Indraccolo S; Randon G; Zulato E; Nardin M; Aliberti C; Pomerri F; Casarin A; Nicoletto MO
Cancer Biol Ther; 2015; 16(2):210-4. PubMed ID: 25607951
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
[TBL] [Abstract][Full Text] [Related]
20. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
Indraccolo S
Adv Exp Med Biol; 2013; 734():37-52. PubMed ID: 23143974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
